Key Highlights
- Net sales for the third quarter of 2026 reached USD 1,715.5 million, up 10.5% from USD 1,553.1 million, with the United States contributing USD 1,007.6 million of the total.
- Diluted earnings per share were USD 0.53 against USD 0.50 a year earlier, while Net Income attributable to Edwards Lifesciences (NYSE:EW) rose to USD 307.5 million from USD 291.1 million.
- Transcatheter mitral and tricuspid therapies sales jumped 44.3% to USD 209.5 million, while transcatheter aortic valve replacement sales rose 8.0% to USD 1,241.6 million.
- An intangible and long-lived asset Impairment of USD 220.2 million, mainly a full write-off of an in-process Research and Development asset, hit the quarter.
Sales Growth Led by Mitral and Tricuspid Products
Edwards Lifesciences (NYSE:EW) filed its Quarterly Report on November 4, 2026, for the period ended September 30. Net sales of USD 1,715.5 million rose 10.5%, with sales outside the United States up 9.7% to USD 707.9 million. Aortic valve replacement products still made up USD 1,241.6 million, helped by the SAPIEN 3 Ultra RESILIA valve, while mitral and tricuspid therapies grew 44.3% on PASCAL, EVOQUE and SAPIEN M3 sales. Surgical products added 2.5% to USD 264.4 million, led by INSPIRIS RESILIA, KONECT RESILIA and MITRIS RESILIA valves. Europe grew 6.9% to USD 414.6 million, and Japan grew 2.2% to USD 92.0 million. The company describes itself as a structural heart disease innovation business, and its regional split shows Rest of World growing fastest at 20.2%.
Impairment and Litigation Swings Shape Profit
The filing shows how one-off items moved results. The USD 220.2 million impairment compares with USD 40.0 million a year earlier. Certain litigation items turned into a net insurance recovery of USD 12.7 million, against USD 90.4 million of expense in the prior-year quarter. Gross Profit was USD 1,346.3 million, a calculated Margin of about 78.5% versus 77.8%, helped by lower Manufacturing expenses and a currency benefit of 0.5 points on margin. Operating Income was USD 299.1 million against USD 307.1 million, and interest income, net, fell to USD 36.5 million from USD 38.6 million on lower yields. Other non-operating income was USD 27.6 million, against USD 2.7 million, on gains tied to the Autus and variable interest entity consolidations.
Nine-Month Earnings Lag Despite Higher Revenue
For the first nine months, net sales climbed 13.5% to USD 5,105.1 million, yet Diluted Earnings per Share slipped to USD 1.61 from USD 1.67. Management attributed the decline to higher tax expense and impairment charges, including a USD 163.6 million loss on impairment tied to variable interest entity investments. Cash and equivalents were USD 3,110.8 million, and Operating Cash Flow was USD 1,266.0 million versus USD 1,144.3 million. Risks named in the filing include Tariff uncertainty, which could raise costs or weaken customer demand. Management also pointed to higher headcount and commercial spending in selling expenses and to heavier research spending on aortic valve and circulatory support technology. Recent approvals include the PASCAL Precision System for tricuspid repair in October 2026.
Where Things Stand
The impairment sits beside healthy operations rather than signalling weak demand. Edwards Lifesciences (NYSE:EW) booked USD 220.2 million for a written-off research asset, yet sales grew 10.5% and quarterly diluted earnings per share edged up to USD 0.53. The September Medicare coverage update for aortic valve replacement and new tricuspid approvals are the filing's main growth markers. Watch how tariffs, tax and further impairments affect the nine-month earnings gap. No guidance figures were included in the extract.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...